Amarin (AMRN) AI Stock Analysis

• Market Cap: $309.89M
• Dividend Yield: N/A
• Average Volume (3M): 92.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -6.31%
• EPS Growth: -115.62%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 20,792,685
• 10 Day Avg. Volume: 95,628
• 30 Day Avg. Volume: 92,857
• PEG Ratio: -1.46
• Price to Book (P/B): 8.20
• Price to Sales (P/S): 17.44
• P/FCF Ratio: -128.50
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 0.20
• Enterprise Value/Gross Profit: 0.50
• Enterprise Value/Ebitda: -0.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.14
• Revenue Forecast (FY): $200.99M

• Rating: 55 Neutral
• Price Target: $17.00 ▲(14.09% Upside)

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and an unattractive earnings-based valuation (negative P/E). These are partly offset by improving operational execution highlighted on the earnings call (U.S. growth, major cost reductions, positive free cash flow target) and moderately supportive technical positioning with price above key moving averages.

Positive Factors

U.S. Revenue Growth

Sustained 34% U.S. product revenue growth, driven by higher net selling price, volume and regained PBM exclusivity, strengthens Amarin's core market position. Durable domestic expansion improves recurring cash generation and reduces reliance on riskier international markets over the medium term.

Cost Reductions and FCF Target

Large, structural SG&A cuts and a management target for positive free cash flow by 2026 materially lower the company's fixed-cost base. If realized, these permanent expense reductions improve financial sustainability, lengthen runway and reduce reliance on external financing in the coming years.

Partnered Ex-U.S. Commercial Model

Shifting to a fully partnered ex-U.S. model (Recordati) transfers commercialization, regulatory and market risk to experienced local partners. This lowers capital intensity, preserves margins and can accelerate scalable international access without heavy incremental investment.

Negative Factors

Ongoing Net Losses and Negative Cash Flow

Persistent unprofitability and negative operating cash flow weaken financial flexibility, erode equity returns and raise funding risk. Achieving sustainable margins and true self-funding depends on execution of cost cuts and revenue trends, making near-term liquidity and capital structure sensitive to setbacks.

Rest-of-World Revenue Decline

Declining Rest-of-World revenues highlight concentrated dependence on the U.S. market and show inconsistent international traction. Limited diversification increases exposure to U.S.-centric risks and means global growth will rely on partner execution and sustained uptake over multiple quarters.

Material Restructuring Costs and Execution Risk

Elevated and increased restructuring charges create an immediate cash drain and raise execution risk: the company must realize the projected $70M OPEX savings by mid-2026 to justify these costs. Failure to convert cuts into sustained savings would pressure profitability and cash runway.

Amarin Business Overview & Revenue Model

Company Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Amarin generates revenue primarily through the sale of its flagship product, Vascepa, which is marketed to healthcare providers and patients for the treatment of cardiovascular conditions. The company earns income from prescription sales in various markets, including the United States, where it has established a robust distribution network. Additionally, Amarin may enter into partnerships or collaborations with other pharmaceutical companies to develop or commercialize new products, which can provide additional revenue streams. The company also benefits from patent protections and exclusivity periods for its products, allowing it to capture a significant share of the market before facing generic competition. Overall, its revenue model relies heavily on the successful promotion and sale of its approved therapeutics, alongside potential future product developments and collaborations.

Amarin Financial Statement Overview

Summary

Amarin faces significant financial challenges with consistent net losses and negative cash flow from operations. Despite slight improvements in revenue growth and free cash flow, operational inefficiencies and profitability issues remain. The low leverage provides some stability, but the negative return on equity and ongoing losses are concerning.

Income Statement

Amarin's income statement shows a challenging financial position with declining revenue over the past few years, although there is a slight revenue growth in the TTM period. The gross profit margin has decreased from its peak in 2021, indicating reduced efficiency in generating profit from sales. The company has been consistently operating at a net loss, with negative EBIT and EBITDA margins, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a relatively stable financial structure with a low debt-to-equity ratio, suggesting limited leverage and potential for financial stability. However, the negative return on equity indicates that the company is not generating positive returns for shareholders. The equity ratio remains strong, indicating a solid capital base relative to total assets.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth in the TTM period, but the company continues to experience negative operating cash flow. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses, but the operating cash flow to net income ratio remains negative, pointing to ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	225.62M	228.61M	306.91M	369.19M	583.19M	614.06M
Gross Profit	88.13M	81.38M	165.54M	242.48M	461.86M	482.62M
EBITDA	-52.20M	-74.18M	-50.70M	-100.69M	14.28M	-12.71M
Net Income	-86.19M	-82.18M	-59.11M	-105.80M	7.73M	-18.00M
Balance Sheet
Total Assets	659.81M	685.35M	831.68M	886.18M	1.07B	966.02M
Cash, Cash Equivalents and Short-Term Investments	286.59M	294.22M	320.66M	309.36M	454.13M	500.93M
Total Debt	6.73M	7.72M	8.74M	10.02M	8.58M	9.15M
Total Liabilities	200.92M	199.17M	279.59M	290.85M	400.97M	338.52M
Stockholders Equity	458.89M	486.18M	552.10M	595.33M	667.10M	627.50M
Cash Flow
Free Cash Flow	-21.86M	-31.02M	6.88M	-179.98M	-66.53M	-22.00M
Operating Cash Flow	-21.86M	-31.03M	6.91M	-179.98M	-66.53M	-21.75M
Investing Cash Flow	-10.58M	-45.98M	-25.62M	175.18M	104.09M	-376.96M
Financing Cash Flow	-2.00M	-1.44M	230.89K	-378.77K	-5.07M	-58.91M

Amarin Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Neutral. The current price of 14.9 is above the 20-day moving average (MA) of 14.29, below the 50-day MA of 15.11, and above the 200-day MA of 14.47, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.25 is Neutral, neither overbought nor oversold. The STOCH value of 51.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMRN.

Amarin Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	80 Outperform	$685.76M	6.08	220.06%	―	79.13%	2798.12%
AMRN	55 Neutral	$309.89M	-3.55	-17.35%	―	-6.31%	-115.62%
RCKT	52 Neutral	$401.50M	-1.62	-74.88%	―	―	18.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALT	51 Neutral	$442.41M	-3.97	-52.61%	―	-61.54%	31.25%
ALDX	50 Neutral	$265.32M	-6.41	-64.31%	―	―	4.23%
CRVS	50 Neutral	$533.23M	-15.05	-35.82%	―	―	79.27%

Amarin Corporate Events

Amarin Appoints David Keenan as COO

David Keenan, Ph.D., has been appointed as the Executive Vice President and Chief Operating Officer of Amarin Corporation, effective October 17, 2025. Dr. Keenan, who joined Amarin in May 2022, brings over 30 years of leadership experience in the biopharmaceutical and medical device industries, with expertise in operations, quality management, and international M&A.

The most recent analyst rating on (AMRN) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.